A Phase 2b clinical trial evaluating NeuroSense Therapeutics’ experimental combination therapy PrimeC in people with amyotrophic lateral sclerosis (ALS) has enrolled its first patient. PARADIGM (NCT05357950) is the company’s next step following the completion of a Phase 2a trial (NCT04165850) wherein the therapy effectively slowed disease…

Treatment with ultrahigh-dose methylcobalamin — the physiologically active form of vitamin B12 — effectively slowed functional decline in people with early-stage amyotrophic lateral sclerosis (ALS) and moderate progression, data from a small Phase 3 trial in Japan show. The findings confirm previous results from a Phase 2/3 trial and…

“Kristin, if you can’t choose joy for yourself, then do it so Todd’s remaining days and years won’t be miserable,” I wrote in my journal a month after my husband, Todd, was diagnosed with ALS. “Do it so your kids can see how to live well, so they…

The Greater Chicago Chapter of the ALS Association is in high gear to end amyotrophic lateral sclerosis (ALS), with multiple awareness and fundraising events taking place throughout June and July. On June 4, after two years of walking in their respective neighborhoods, supporters returned to Cantigny Park in…

Ever since I was diagnosed with ALS in 2010, I’ve become sensitive to how ALS is represented in the movies. And I’ll admit to voicing my opinion about the topic in several of my past columns. So you can imagine my glee and pride when, six months…

Albrioza, formerly called AMX0035, has been given conditional approval by Health Canada for the treatment of amyotrophic lateral sclerosis (ALS). The decision marks a first approval for Albrioza by a regulatory authority in any country and the first new ALS therapy to enter the Canadian market since 2018.

Treatment with the experimental gold nanocrystal therapy CNM-Au8 decreased the risk of mortality by 64% among people with early amyotrophic lateral sclerosis (ALS), compared to what would be expected without treatment, according to new analyses from the RESCUE-ALS clinical trial. The findings were presented by Clene Nanomedicine,…

Early use of Biogen’s tofersen significantly slows disability progression, as well as a decline in lung function, muscle strength, and quality of life in amyotrophic lateral sclerosis (ALS) patients with mutations in the SOD1 gene, compared with a six-month delay in starting treatment. These benefits were accompanied by pronounced and sustained…

I’m all in when it comes to celebrating milestones, and as many of my readers know, I’m a glass-half-full person. So when June arrived, I didn’t have to look far for my first reason to celebrate. Happy 5 years to me! This month, I’m celebrating the five-year milestone of…

Lisa Cross thought having amyotrophic lateral sclerosis (ALS) meant she would have to give up on acting and the theater. A longtime stage actor, Cross, 66, had worked in just about every aspect of the entertainment industry: she was a dancer and singer; a director, choreographer, and teacher; an…